DR30206 plus standard therapy for advanced GI cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called DR30206 combined with standard therapy for advanced gastrointestinal cancers. It may be an option if you have colorectal, esophageal, gastric, or gastroesophageal junction cancer and have had little or no prior chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer, esophageal adenocarcinoma, gastric adenocarcinoma, or gastroesophageal junction adenocarcinoma that cannot be removed by surgery or has spread.
- You have had little or no prior chemotherapy for advanced cancer. If you had chemotherapy in the past, it was only one previous treatment.
- Your cancer is not MSI-H or dMMR (special genetic types).
- You have at least one tumor that can be measured on scans.
- You are generally healthy enough for daily activities (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DR30206 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how the body processes it.
This trial tests a new drug combination for people with advanced stomach or gastroesophageal junction cancer that has grown after earlier treatment. It aims to see if adding these drugs can help shrink tumors or slow the disease.
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
This trial tests a new drug, MRG007, combined with other treatments for advanced colorectal cancer. The goal is to see if this combination can shrink tumors or slow the cancer's growth when standard treatments have not worked.
This trial tests a new experimental drug (HNF4α srRNA) given through a vein for people with advanced colorectal cancer that has not responded to or cannot be treated with standard therapies. The goal is to see if this treatment can help shrink or slow the growth of the cancer.
This trial tests a new drug (RC148) combined with standard chemotherapy as a first treatment for colorectal cancer that has spread or cannot be removed. The goal is to see if this combination works better than chemotherapy alone.
Hear when a new Gastrointestinal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.